PARADIGM BIOPHARMACE

PAR
Delayed Australian Stock Exchange - 12:10 2022-12-02 am EST
1.450 AUD -3.33%

Turn to zoom
Prev.1.45000000
Open1.50000000
High1.50000000
Low1.41000000
Volume327 780
Latest news
11/21
11/21
11/18
11/10
Chart PARADIGM BIOPHARMACEUTICALS LIMITED
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralNeutralNeutral
Resistance1,702,141,99
Spread/Res.-15%-32%-27%
Spread/Supp.13%66%52%
Support1,280,880,96
Financials
Sales 2023 - - -
Net income 2023 -58,5 M -39,8 M -39,8 M
Net Debt 2023 - - -
P/E ratio 2023 -7,25x
Yield 2023 -
Capitalization 413 M 281 M 281 M
Capi. / Sales 2023 -
Capi. / Sales 2024 -
Nbr of Employees -
Free-Float 93,7%
Company
Paradigm Biopharmaceuticals Limited is a late-stage drug development company that is engaged in researching and developing therapeutic products for human use. The Company is focused on developing and commercializing pentosan polysulfate sodium (PPS) for the treatment of pain associated with...
Sector :
Other Biotechnology & Medical Research
Calendar :
2023-02-20 Presentation

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,45 AUD
Average target price 2,20 AUD
Spread / Average Target 51,7%